folate receptor

May 7, 2018

Phase 3 Trial of Mirvetuximab Soravtansine in Ovarian Cancer OK’d to Continue as Planned

News

A Phase 3 trial evaluating ImmunoGen’s mirvetuximab soravtansine (IMGN853) in platinum-resistant ovarian cancer patients is on its way to achieving its objectives, an interim futility analysis shows. As a result, the FORWARD ... Read more

March 26, 2018

Phase 1 Trial Finds TPIV200 Is Safe, Delays Recurrence in Ovarian, Breast Cancer

News

An investigational vaccine called TPIV200 was found to be safe and generated strong T-cell immunity against tumor cells, significantly delaying recurrence in breast and ovarian cancer patients who had achieved complete ... Read more